written on 19.05.2014
Tags:
,

ATS 2014: InterMune, Boehringer face off in IPF

TAGS: ,

InterMune's idiopathic pulmonary fibrosis (IPF) drug pirfenidone may have a survival benefit over Boehringer Ingelheim's IPF treatment nintedanib, but Phase III results presented at the American Thoracic Society (ATS) 2014 Conference in San Diego make it…

Latest Report